Skip to main content

Peer Review reports

From: SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI

Original Submission
26 Jan 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
25 Mar 2023 Reviewed Reviewer Report - İbrahim Rencüzoğulları
30 Apr 2023 Reviewed Reviewer Report
6 May 2023 Reviewed Reviewer Report
21 May 2023 Author responded Author comments - Jian Li
Resubmission - Version 3
21 May 2023 Submitted Manuscript version 3
24 May 2023 Author responded Author comments - Jian Li
Resubmission - Version 4
24 May 2023 Submitted Manuscript version 4
25 May 2023 Author responded Author comments - Jian Li
Resubmission - Version 5
25 May 2023 Submitted Manuscript version 5
26 May 2023 Reviewed Reviewer Report - İbrahim Rencüzoğulları
27 May 2023 Reviewed Reviewer Report
10 Jun 2023 Author responded Author comments - Jian Li
Resubmission - Version 6
10 Jun 2023 Submitted Manuscript version 6
15 Jun 2023 Author responded Author comments - Jian Li
Resubmission - Version 7
15 Jun 2023 Submitted Manuscript version 7
15 Jun 2023 Author responded Author comments - Jian Li
Resubmission - Version 8
15 Jun 2023 Submitted Manuscript version 8
Publishing
16 Jun 2023 Editorially accepted
27 Jun 2023 Article published 10.1186/s12872-023-03353-1

You can find further information about peer review here.

Back to article page